BSD Medical Reports Published Study Demonstrates Improved Survival for Pancreatic Cancer Patients Treated Using the BSD-2000

Symbols: BSDM
Posted in: News, FDA
Share

BSD Medical Corporation (NASDAQ: BSDM), today reported that study results demonstrate a survival benefit, without an increase in toxicity, from the addition of hyperthermia for the treatment of advanced pancreatic cancer patients.


 
 
< Previous
Ocean Rig UDW Inc. Announces Additional Well Contracts
Next >
Oragenics, Inc. Receives U.S. Patent for IVIAT Platform Technology
Share
Printer-friendly version
Send to friend
We're Loving

Benzinga's Premium Memberships

Benzinga's News Delivered Free

Brain Trust